Transdermal contraceptive hormones delivery
Inventors
Rossi, Thomas M. • Foegh, Marie • Kydonieus, Agis
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9782419-B2
Publication Date
2017-10-10
Expiration Date
Abstract
Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.
Core Innovation
The invention relates to preventing pregnancy in a woman using transdermal administration of contraceptively effective hormones in a variable treatment-cycle regimen. During an eight week or a twelve week treatment cycle, a treatment interval of seven weeks or eleven weeks is followed by a rest interval of one week, with transdermal delivery provided by successive weekly applications of multiple transdermal hormone delivery treatment interval devices.
The treatment interval is configured to transdermally administer a contraceptively effective amount of a progestin and an estrogen throughout the treatment interval by applying three or seven transdermal hormone delivery treatment interval devices, one for each week of the treatment interval. During the rest interval, the regimen switches to a low dose transdermal hormone delivery device that delivers low dose progestin and low dose estrogen while providing a defined fraction of the hormone amounts delivered by each treatment interval device.
The rest interval device is defined to deliver between 25% and 75% of the amount of progestin and between 25% and 75% of the amount of estrogen as delivered by each treatment interval device. The method is arranged so that the woman experiences menstruation during the rest interval, and it includes selection of specific estrogen and progestin constituents for the treatment interval and rest interval devices.
Claims Coverage
The document includes one independent claim describing the core method of preventing pregnancy using successive weekly transdermal treatment-interval devices and a one-week rest-interval transdermal device with defined reduced hormone delivery, with menstruation occurring during the rest interval. The dependent claims refine the regimen by specifying additional constraints and selections for the hormone constituents and delivery relationships, and by defining kit structures and/or device characteristics.
Successive weekly transdermal treatment with multiple hormone delivery devices
During an eight week or a twelve week treatment cycle having a treatment interval of seven weeks or eleven weeks and a rest interval of one week, transdermally administering a contraceptively effective amount of a progestin and an estrogen during the treatment interval by successive weekly applications of three or seven transdermal hormone delivery treatment interval devices, one for each week of the treatment interval.
One-week rest interval transdermal low-dose delivery with defined fraction
Transdermally administering low dose progestin and low dose estrogen throughout the rest interval by application of a low dose transdermal hormone delivery device during the rest interval wherein the rest interval device delivers between 25% and 75% of the amount of progestin and between 25% and 75% of the amount of estrogen as delivered by each treatment interval device.
Menstruation during the rest interval
The method whereby the woman experiences menstruation during the rest interval.
Overall, claim coverage centers on a transdermal contraceptive regimen that combines successive weekly treatment-interval devices delivering progestin and estrogen with a one-week rest interval device delivering reduced low doses defined as 25% to 75% of the treatment-interval hormone amounts, arranged so menstruation occurs during the rest interval, with specified selection options for estrogen and progestin constituents.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?